Lacosamid Puren (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. By stabilizing these channels, it reduces repetitive neuronal firing and limits the spread of abnormal electrical activity that leads to seizures.

The specific dose of Lacosamid Puren is determined by the prescribing clinician based on the patient’s age, weight, renal and hepatic function, and overall treatment plan. Dosage adjustments are individualized and should follow the prescriber’s instructions.

Safety data for lacosamide in pregnancy and lactation are limited. Clinicians should evaluate the potential benefits against possible risks before prescribing to pregnant or nursing women, and discuss alternative options when appropriate.

To order Lacosamid Puren, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lacosamide’s unique mechanism—enhancing slow inactivation of sodium channels—differs from many older agents that target fast inactivation. This can provide effective seizure control with a distinct side‑effect profile, making it a valuable add‑on option when patients do not achieve adequate control with other antiepileptics.

Lacosamid Puren should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Avoid freezing and keep the product away from extreme temperature fluctuations.

Lacosamid Puren is supplied as an intravenous solution and is administered by a healthcare professional via intravenous infusion. The rate and duration of infusion are determined by the prescriber and follow institutional protocols.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation, which may lead to arrhythmias, and rare severe skin reactions like Stevens‑Johnson syndrome. Patients should be monitored for cardiac changes and any signs of hypersensitivity during treatment.

Lacosamid Puren is contraindicated in patients with known hypersensitivity to lacosamide or any of its excipients. Caution is advised for individuals with significant cardiac conduction disorders, severe hepatic impairment, or those taking interacting medications that cannot be managed.